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Abstract
The diagnosis of celiac disease (CD) is currently based on serology and intestinal biopsy,
with detection of anti-tissue transglutaminase (tTG) IgA antibodies recommended as the
first-line test. Emphasizing the increasing importance of serological testing, new guidelines
and evidence suggest basing the diagnosis solely on serology without confirmatory biopsy.
Enzyme immunoassays (EIAs) are the established approach for anti-tTG antibody detec-
tion, with the existing point-of-care (POC) tests lacking sensitivity and/or specificity.
Improved POC methods could help reduce the underdiagnosis and diagnostic delay of CD.
We have previously developed rapid homogenous immunoassays based on time-resolved
Fo¨rster resonance energy transfer (TR-FRET), and demonstrated their suitability in sero-
diagnostics with hanta- and Zika virus infections as models. In this study, we set out to
establish a protein L -based TR-FRET assay (LFRET) for the detection of anti-tTG antibod-
ies. We studied 74 patients with biopsy-confirmed CD and 70 healthy controls, with 1) the
new tTG-LFRET assay, and for reference 2) a well-established EIA and 3) an existing com-
mercial POC test. IgG depletion was employed to differentiate between anti-tTG IgA and
IgG positivity. The sensitivity and specificity of the first-generation tTG-LFRET POC assay
in detection of CD were 87.8% and 94.3%, respectively, in line with those of the reference
POC test. The sensitivity and specificity of EIA were 95.9% and 91.9%, respectively. This
study demonstrates the applicability of LFRET to serological diagnosis of autoimmune dis-
eases in general and of CD in particular.
Introduction
The diagnosis of celiac disease (CD) is conventionally based on the combination of serology
and duodenal biopsy, with detection of IgA anti-tTG antibodies recommended as the first-line
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test [1–3]. Total IgA is measured to avoid false negative results in patients with IgA deficiency
[1–4]. Other serological markers of CD include antibodies against endomysium antigen
(EMA) and deamidated gliadin peptides (DGP), however, somewhat laborious measuring
techniques and subjective interpretation (EMA) or weaker specificity (DGP) hampers their
use in diagnostics. Additionally, HLA (human leukocyte antigen) testing may aid in ruling out
CD, as almost all patients with CD display HLA-DQ2.5 or -DQ8 [5]. Emphasizing the increas-
ing importance of serology, European guidelines allow the diagnosis of symptomatic children
to be based on serological markers only [4]. In fact, recent evidence suggests that serological
diagnosis would suffice for adults and asymptomatic children [6, 7].
Enzyme immunoassays (EIA) and point-of-care (POC) tests serve as detection methods for
anti-tTG antibodies. EIA, with its high sensitivity and specificity, is the most widespread
method. However, it requires dedicated laboratory infrastructure, and the results are available
at best within some hours. The majority of POC diagnostics is performed using lateral flow
assays (LFA), which unlike EIA are rapid but suffer from lower sensitivity (91% vs. 94%,
respectively) and specificity (95% vs. 97%, respectively) in detecting biopsy-confirmed CD [8,
9]. Lacking quantitation, the existing anti-tTG IgA POC tests cannot replace EIAs in the diag-
nostic algorithm of CD as per the European Society for Paediatric Gastroenterology Hepatol-
ogy and Nutrition (ESPGHAN) [4]. Also, from the follow-up perspective, a quantitative result
would be desirable.
Better POC tests could lower the testing threshold and help reduce the diagnostic delay and
underdiagnosis of CD. It is estimated that 83–90% of CD patients remain undiagnosed [10],
having a markedly reduced quality of life as compared to those diagnosed and treated [11].
Moreover, delayed diagnosis [12, 13] is associated with persistent symptoms [14] leading to
increased use of healthcare services, and a decreased quality of life even after the diagnosis and
treatment [15].
TR-FRET (time-resolved Fo¨rster resonance energy transfer) is a phenomenon occurring
when two fluorophores, donor and acceptor, are in close proximity. Excitation of the donor
leads to energy transfer to the acceptor, which then emits the energy at a characteristic wave-
length. The TR-FRET efficiency depends inversely on the distance between the two fluoro-
phores. Background autofluorescence is minimized by time-resolved measurement, enabled
by chelated lanthanide fluorophores with a long fluorescence half-life. TR-FRET has been
employed widely in research and diagnosis to investigate e.g. protein-protein interactions and
disease markers [16].
We have previously developed a rapid wash-free TR-FRET -based method for antibody
detection, termed protein L FRET assay (LFRET) [17]. LFRET employs a donor-labeled anti-
gen, and an acceptor-labeled protein L that binds the kappa (κ) light chains of all immuno-
globulin classes. If the clinical sample contains antibodies against the antigen, they will bring
the fluorophores to close proximity. Thus, the TR-FRET signal tells that the sample contains
the antibodies of interest. The LFRET signal can be measured without additional steps shortly
after combining the sample with the reagent mix, allowing for rapid point-of-care diagnosis.
We have provided proof-of-concept for the LFRET assay in serodiagnostics using hanta- and
Zika virus infections as models [18, 19].
To achieve a test quicker than EIA and with a higher diagnostic utility compared to LFA,
and to demonstrate the applicability of the LFRET approach to autoimmune diagnosis, we set
out to establish an LFRET assay for the detection of IgA-class anti-tTG antibodies. Using a
panel of serum/plasma samples from patients with biopsy-confirmed CD and healthy controls,
we herein demonstrate that tTG-LFRET can indeed be utilized in serological diagnosis of CD
with a performance comparable to existing POC tests.
LFRET, a novel rapid anti-tTG antibody assay
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Materials and methods
Samples
The study included serum and/or plasma samples of 74 Finnish patients, 43 children and 31
adults, with CD confirmed by a duodenal biopsy showing villous atrophy and crypt hyperpla-
sia corresponding to Marsh classes 3A-C. HLA-DQ2.5 and -DQ8 molecules, encoded by the
HLA-DQA1 and DQB1 alleles, were analyzed as described [20, 21]. DQ2.5, DQ8 or both were
positive for 59, 5 and 4 patients, respectively. With 6 individuals, the HLA status was not
analyzed.
The control group comprised serum and/or plasma samples from 70 healthy individuals,
including 47 children and 23 adults. DQ2.5, DQ8 or both were positive for 34, 31 and 4 indi-
viduals, respectively.
The study was approved by the Ethics Committee of Kuopio University Hospital and writ-
ten informed consent was obtained from all subjects (from parents/guardians of all children
and the children themselves, if >10 years of age).
Proteins
Recombinant protein L (Thermo Scientific) was labeled with Alexa Fluor 647 (AF) to yield
AF-labeled protein L (AF-L), as described [18]. Europium-labeled tTG (Eu-tTG) was gener-
ated by labeling baculovirus/Sf9-expressed tTG (Diarect AG) with QuickAllAssay Eu-chelated
protein labeling kit (BN Products and Services) according to the manufacturer’s instructions.
IgG-free bovine serum albumin (BSA) used in LFRET assay was from Jackson ImmunoRe-
search Inc.
tTG-LFRET assay
The LFRET assay principle has been described previously [17, 18], and is illustrated in Fig 1.
Unlike in those papers, the results here are given as averages of normalized TR-FRET signal
values, not divided by the TR-FRET signal of the negative control. To establish an LFRET
assay for anti-tTG antibodies the concentrations of assay components were optimized by
cross-titration, using panels of 5 to 15 samples shown anti-tTG-IgA positive or negative by
FEIA (fluorescent enzyme immunoassay). The optimal on-plate serum dilution was found to
be 1/100, and the optimal on-plate concentrations for AF-L and Eu-tTG, 250 nM and 5 nM,
respectively. To determine the incubation time, measurements were done at 0, 7, 15, 22, 30, 45,
60 and 90 minutes after mixing the reagents. TR-FRET signals were measured with Wallac
Victor2 fluorometer (PerkinElmer) and normalized as described previously [22].
IgG depletion
To distinguish between anti-tTG IgA- and IgG-class antibodies, GullSORB (Meridian Biosci-
ence, Inc.) was used to deplete the samples of IgG, as described [18]. All samples were studied
by tTG-LFRET with and without IgG depletion.
Reference methods and statistical analyses
The tTG IgA reference test was EliA Celikey IgA (Thermo Scientific, Phadia GmbH), a FEIA
used widely by clinical laboratories. Total IgA was measured with an accredited in-house
method of HUSLAB (Hospital District of Helsinki and Uusimaa, Laboratory Services, Fin-
land). If the total IgA measurement was indicative of selective IgA deficiency, tTG IgG was
measured by EliA Celikey IgG (Thermo Scientific, Phadia GmbH).
LFRET, a novel rapid anti-tTG antibody assay
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A commercial rapid lateral flow test (Celiac Disease Quick Test, Biohit) for anti-tTG anti-
bodies performed according to the manufacturer’s instructions was used as an additional
reference.
All statistical analyses were performed with R version 3.5.1.
Results
tTG-LFRET incubation time, cutoff values and performance
An LFRET assay for detection of anti-tTG antibodies (tTG-LFRET) was set up using recombi-
nant Eu-labeled tTG antigen and AF-labeled protein L. The assay conditions were first opti-
mized utilizing 15 selected samples (included in the 144-sample panel) known to be negative
(n = 7) or positive (n = 8) for IgA-class anti-tTG antibodies. Then, using the optimized condi-
tions, all 144 samples were tested with tTG-LFRET. While most of the CD patient samples
were anti-tTG positive already in the first TR-FRET measurement immediately after mixing
the reagents, the best balance between sensitivity, specificity and incubation time was obtained
at 22 minutes’ assay time (S1 Fig and S1 Table).
To determine the assay cutoff we measured the tTG-LFRET signals for 67 tTG-antibody
negative samples, and set the LFRET cutoff at mean plus two standard deviations (SD) (35.438
+ 2 × 5.316 = 46.07 counts).
Fig 1. Simplified protocol for tissue transglutaminase protein L TR-FRET assay. Eu-tTG = Europium-labeled tissue
transglutaminase, AF-L = Alexa Fluor™ 647 -labeled protein L; TR-FRET = time-resolved Fo¨rster resonance energy
transfer; RT = room temperature. We used TBS-BSA (50mM Tris-HCl, 150mM NaCl, pH 7.4, 0.2% BSA) for all
component dilutions. On-plate serum dilution was 1/100 and reagent concentrations were 250 nM for AF-L and 5 nM
for Eu-tTG. For further details, see the previous publication [18].
https://doi.org/10.1371/journal.pone.0225851.g001
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We then assessed the diagnostic performance of the tTG-LFRET assay by analyzing alto-
gether 144 serum/plasma samples from 74 CD patients and 70 healthy controls with HLA-
associated genetic risk for CD. The sensitivity and specificity of tTG-LFRET in detection of
biopsy-proven CD were 87.8% (65/74) and 94.3% (66/70), respectively (Table 1).
Comparison of tTG-LFRET with FEIA and lateral flow
To compare tTG-LFRET performance with existing assays, we analyzed the above described
sample panel using anti-tTG IgA FEIA and a commercial anti-tTG lateral flow assay. By apply-
ing the manufacturer-defined cutoffs and considering equivocal results as positive, the sensi-
tivity of anti-tTG FEIA in detection of CD was 95.9% (71/74) and the specificity was 91.4%
(64/70) (Table 1). The respective values for the commercial lateral flow assay were 87.8% (65/
74) and 94.3% (66/70). The samples incorrectly identified by any of the methods have been
listed in Table 2.
Notably, all samples (n = 42) with a high FEIA result (above 70 U/ml) yielded positive
tTG-LFRET results (Fig 2). The Pearson correlation between LFRET and FEIA results was
0.85.
IgG depletion in tTG-LFRET
In an earlier study we employed IgG depletion to distinguish between IgM and IgG in an
infectious disease application of LFRET [18]. Here we used the same approach to determine if
the sample is anti-tTG IgA-positive or IgA-negative yet IgG-positive. After IgG depletion,
using a constant cutoff (mean + 2 × SD, equal to 34.392 + 2 × 5.117 = 44.63 counts), the
LFRET assay sensitivity and specificity would be 77.0% (57/74) and 95.7% (67/70), respectively
(Fig 3).
The reduction in tTG-LFRET signal (in %) due to IgG depletion was determined for each
of the 144 samples. The average reduction plus 2.5 × SD, corresponding to a 59% reduction in
tTG-LFRET signal, was chosen as cutoff, with greater reduction taken as indication of IgG-
class LFRET positivity. Hence, samples in which upon IgG depletion the tTG-LFRET signal
both 1) fell down by>59% and 2) went beyond the cutoff of 44.63 counts, were considered
anti-tTG IgG-positive yet IgA-negative. As no such samples were found in the panel, two of
them were obtained from HUSLAB to validate the threshold. Upon IgG depletion, the
tTG-LFRET signal levels for these samples decreased by 70% and 87% and went below the
Table 1. Sensitivity and specificity of LFRET, FEIA and LFA by age group and altogether.
Group Subjects TP FP TN FN Sensitivity Specificity
tTG-LFRET Children 90 43 3 44 0 100.0% 93.6%
Adults 54 22 1 22 9 71.0% 95.7%
Total 144 65 4 66 9 87.8% 94.3%
FEIA Children 90 43 6 41 0 100.0% 87.2%
Adults 54 28 0 23 3 90.3% 100.0%
Total 144 71 6 64 3 95.9% 91.4%
LFA Children 90 43 3 44 0 100.0% 93.6%
Adults 54 22 1 22 9 71.0% 95.7%
Total 144 65 4 66 9 87.8% 94.3%
TP = true positive, FP = false positive, TN = true negative, FN = false negative. tTG-LFRET = tissue transglutaminase protein L–based Fo¨rster resonance energy transfer
assay. FEIA = fluorescent enzyme immunoassay (Phadia EliA Celikey IgA). LFA = Lateral flow assay (Biohit Celiac Disease Quick Test).
https://doi.org/10.1371/journal.pone.0225851.t001
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positivity cutoff; hence the samples were correctly identified as anti-tTG IgA-negative yet IgG-
positive (Fig 4).
Discussion
We established a rapid LFRET assay for the detection of anti-tTG IgA-class antibodies
(tTG-LFRET) for serological screening of celiac disease (CD). CD affects 1% of world popula-
tion and the typical diagnostic delay is 5–10 years [12, 13]. In both developed and resource-
poor countries, the vast majority of patients currently remain undiagnosed. Patients with
undiagnosed and untreated CD suffer from decreased quality of life and increased risk of vari-
ous conditions including neuropathy, liver disease as well as osteoporosis [2, 5]. Thus, low-
threshold diagnostic testing and screening of risk groups such as first-degree relatives of CD
patients is warranted. Reliable anti-tTG POC diagnostics could lower the threshold for CD
screening and help overcome the diagnostic delay.
Herein we harnessed LFRET [17], previously applied in infectious disease diagnostics [18,
19], for an autoimmune disease identified by tTG-specific IgA antibodies. This paves way for
development of LFRET assays for other autoimmune diseases. While in CD the tTG autoanti-
gen is well-characterized, the less defined antigens in some other autoimmune diseases provide
a challenge for POC diagnostics. Nevertheless, with well-defined autoantigens, e.g. ANCA-
associated vasculitis, anti-GBM disease, pemphigus and pemphigoid could be suitable targets
for LFRET-based assay development.
Table 2. Samples identified incorrectly by any of the methods used.
Sample Group CD status LFRET (counts, mean of duplicates ± SD) FEIA (U/ml) LFA Incorrectly identified by
1 Children + 42 ± 8.1 12 + LFRET
2 Adults + 35 ± 6.1 1.4 - LFRET, FEIA, LFA
3 Adults + 35 ± 3.8 13 + LFRET
4 Adults + 36 ± 9.8 20 + LFRET
5 Adults + 41 ± 9.6 15 + LFRET
6 Adults + 43 ± 5.5 6.3 - LFRET, FEIA, LFA
7 Adults + 46 ± 1.7 15 - LFA
8 Adults + 37 ± 4.3 20 + LFRET
9 Adults + 34 ± 2.3 1 - LFRET, FEIA, LFA
10 Adults + 46 ± 1.1 13 - LFA
11 Adults + 48 ± 12.5 14 - LFA
12 Adults + 54 ± 4.6 33 - LFA
13 Adults + 43 ± 0.9 15 - LFRET, LFA
14 Adults + 42 ± 1.1 10 - LFRET, LFA
15 Children - 39 ± 5.3 10 - LFRET, LFA
16 Children - 47 ± 1.6 22 + LFRET, FEIA, LFA
17 Children - 47 ± 0.8 18 - LFA
18 Children - 36 ± 1.8 14 + FEIA, LFA
19 Children - 79 ± 9.9 35 - LFRET, FEIA
20 Adults - 27 ± 13.8 1 + LFA
21 Adults - 46 ± 0.3 1.7 - LFRET
CD status = celiac disease (CD) status as defined by biopsy (+ = CD,— = no CD). LFRET (protein L TR-FRET assay) / FEIA (fluorescent enzyme immunoassay) / LFA
(lateral flow assay) = CD status as suggested by each method, darker background indicating a result suggestive of CD. For LFRET and FEIA, quantitative results are
included, as photons for LFRET and as U/ml for FEIA. Cutoffs for LFRET and FEIA are 45 counts and 7 U/ml, respectively.
https://doi.org/10.1371/journal.pone.0225851.t002
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The sensitivity and specificity of tTG-LFRET for biopsy-confirmed CD were 87.8% and
94.3%, respectively. While the commercial LFA was equal to tTG-LFRET, FEIA exhibited
higher sensitivity (95.9%) but lower specificity (91.9%). In line with our LFA results, the exist-
ing anti-tTG IgA POC tests have been shown to identify biopsy-confirmed CD with a pooled
sensitivity and specificity of 90.5% (95% CI 82.3% –95.1%) and 94.8% (95% CI 92.5% –96.4%),
respectively [9]. EIAs have been shown to perform with a slightly lower pooled sensitivity of
93.0% (95% CI 91.2% –94.5%), yet with a higher pooled specificity of 96.5% (95% CI 95.2% –
97.5%) [8]. Interestingly, all of our CD patients anti-tTG negative by FEIA were likewise nega-
tive by tTG-LFRET and LFA (Table 2). Lowering the tTG-LFRET cutoff, for enhanced sensi-
tivity of 93.2%, would decrease the specificity to 81.4%. In general, the somewhat lower
sensitivity of tTG-LFRET compared to FEIA was confined to samples weakly positive in the
latter assay (Fig 2), and might result from the europium label masking some of the tTG epi-
topes. Another contributing factor could be the variation in immunoglobulin light chain
Fig 2. Anti-tTG-IgA FEIA results (x-axis) compared to LFRET results (y-axis) without IgG depletion. FEIA = fluorescent enzyme immunoassay. LFRET = protein
L–based time-resolved Fo¨rster resonance energy transfer assay. FEIA result is expressed as U/ml. LFRET result is expressed as average of normalized acceptor
wavelength emission counts from two replicates of the same sample, with two consecutive measurements from both replicates. Patients with biopsy-confirmed celiac
disease (CD) are marked with a darker spot. The solid lines indicate cutoffs for FEIA and LFRET, with the area between 7 and 10 U/ml corresponding to an equivocal
result for FEIA. FEIA cutoffs are set as determined by the manufacturer. LFRET cutoffs were determined by measuring the tTG-LFRET signals for 67 tTG-antibody
negative samples (as defined by FEIA) and setting the LFRET cutoff at the mean LFRET signal plus two standard deviations (SD) (35.438 + 2 × 5.316 = 46.07 counts).
Pearson correlation coefficient between FEIA and LFRET results is 0.85.
https://doi.org/10.1371/journal.pone.0225851.g002
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composition: the anti-tTG antibodies in some individuals might mostly have light chains of
type λ, nonbinding protein L. Patients with a high-positive FEIA result of>70 U/ml, i.e., >10
times the upper limit of normal (ULN) were all correctly positive in tTG-LFRET, both with
and without IgG depletion. This could reflect greater anti-tTG antibody repertoire with anti-
bodies containing both κ and λ light chains. An anti-tTG IgA result of>10x ULN is among
the requirements of ESPGHAN criteria for CD diagnosis without biopsy [4]. With IgG deple-
tion, our tTG-LFRET cutoff could be set at 60 counts (Fig 3, dashed lines): A tTG-LFRET
result higher than this equals a FEIA result of>10x ULN (> 70 U/ml) with 95% sensitivity
(40/42 samples) and 100% specificity (142/142). Indeed, all of the patients exceeding this cutoff
had biopsy-confirmed CD. Thus, individuals with an IgG-depleted tTG-LFRET result above
60 can be considered to have CD at a high degree of certainty, possibly without the need for
biopsy. Importantly, such patients made up more than a half of those diagnosed with CD in
the present study (40/74).
Fig 3. Anti-tTG-IgA FEIA results (x-axis) compared to LFRET results (y-axis) with IgG depletion. FEIA = fluorescent enzyme immunoassay. LFRET = protein L–
based time-resolved Fo¨rster resonance energy transfer assay. FEIA result is expressed as U/ml. LFRET result is expressed as average of normalized acceptor wavelength
emission counts from two replicates of the same sample, with two consecutive measurements from both replicates. Patients with biopsy-confirmed celiac disease (CD)
are marked with a darker spot. The solid lines indicate cutoffs for FEIA and LFRET, with the area between 7 and 10 U/ml corresponding to an equivocal result for
FEIA. FEIA cutoffs are set as determined by the manufacturer. LFRET cutoffs were determined by measuring the tTG-LFRET signals for 67 tTG-antibody negative
samples (as defined by FEIA) and setting the LFRET cutoff at the mean LFRET signal plus two standard deviations (SD) (34.392 + 2 × 5.117 = 44.63 counts). The
dashed line represents x10 upper limit of normal (ULN) for FEIA, and for LFRET a cutoff for detection of samples with a FEIA result above x10 ULN. Pearson
correlation coefficient between FEIA and LFRET (with IgG depletion) results is 0.83.
https://doi.org/10.1371/journal.pone.0225851.g003
LFRET, a novel rapid anti-tTG antibody assay
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Interestingly, IgG depletion reduced the tTG-LFRET signal to a varying extent in most of
the anti-tTG positive samples (Fig 4). This suggests that not only anti-tTG IgA, but also anti-
tTG IgG contributes to the tTG-LFRET signal. Anti-tTG IgG contribution to tTG-LFRET sig-
nal in samples with low concentration of anti-tTG IgA could also explain the enhanced sensi-
tivity of tTG-LFRET for CD diagnosis without IgG depletion (87.8% vs 77.0% with IgG
depletion, Figs 1 and 2). In the study population, this does not decrease the specificity of the
method for CD diagnosis. This is in line with previous studies showing that anti-tTG IgG has a
high specificity for CD comparable to anti-tTG IgA, albeit lower sensitivity [23].
In conclusion, our study shows that the LFRET approach is applicable to detection of IgA
autoantibodies and serological diagnostics of autoimmune diseases. The assay appears highly
specific in detection of CD, yet somewhat less sensitive. A homogenous approach, the LFRET
is considerably faster than EIA, paralleling LFAs in both time and diagnostic performance.
Unlike the LFA used, the LFRET provides a numeric result.
Supporting information
S1 Fig. Sensitivity and specificity (y-axis) of tTG-LFRET (tissue transglutaminase protein
L TR-FRET assay) for CD (celiac disease) at different incubation times (x-axis). We chose
22 minutes as the incubation time to achieve the best balance between sensitivity, specificity
and assay time.
(TIF)
S1 Table. Sensitivity and specificity of tTG-LFRET (tissue transglutaminase protein L
TR-FRET assay) for CD (celiac disease) at different incubation times. We chose 22 minutes
(bolded) as the incubation time to achieve the best balance between sensitivity, specificity and
assay time.
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